Lördag 21 December | 18:06:19 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-08-19 14:30 Kvartalsrapport 2025-Q2
2025-05-18 14:30 Kvartalsrapport 2025-Q1
2025-02-14 N/A Årsstämma
2025-02-14 15:00 Bokslutskommuniké 2024
2024-11-29 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-31 - Årsstämma
2024-05-22 - Kvartalsrapport 2024-Q1
2024-05-17 - X-dag ordinarie utdelning EEVIA 0.00 SEK
2024-02-14 - Bokslutskommuniké 2023
2023-11-22 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-06-26 - Årsstämma
2023-05-26 - X-dag ordinarie utdelning EEVIA 0.00 SEK
2023-05-16 - Kvartalsrapport 2023-Q1
2023-02-24 - Bokslutskommuniké 2022
2022-11-25 - Kvartalsrapport 2022-Q3
2022-10-11 - Extra Bolagsstämma 2022
2022-08-29 - Kvartalsrapport 2022-Q2
2022-06-22 - X-dag ordinarie utdelning EEVIA 0.00 SEK
2022-06-21 - Årsstämma
2022-05-27 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-12-09 - Extra Bolagsstämma 2021
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-13 - Kvartalsrapport 2021-Q2
2021-06-22 - Årsstämma
2021-05-18 - Kvartalsrapport 2021-Q1

Beskrivning

LandFinland
ListaSpotlight
SektorHandel & varor
IndustriDetaljhandel
Eevia Health är verksamma inom life science. Bolaget erbjuder produktionsprotokoll och procedurer för att leverera ekologiska produkter till internationella kunder. Produkterna säljs till företagskunder och inkluderar ingredienser till producenter av kosttillskott, livsmedel och kosmetika på global basis. Produkterna innefattar exempelvis blåbär, chaga-svamp och tallbark. Eevia Health grundades 2017 och har sitt huvudkontor i Seinäjoki, Finland.
2024-11-18 11:49:18

Eevia Health Plc ("Eevia" or "The Company") will publish its Interim report for the third quarter on November 29 due to the onboarding of a new Board and one large unforeseen urgent project that appeared a week ago.

Eevia shareholders elected a new Board on November 4. The Board has met once for a constitutional meeting and will meet again on November 20. However, as the board members, including the Chairman, are still being inducted into the Company, the Company wants to give the Board more time to review the status and the Interim Report.

In addition, the Company has been approached for a large, urgent project that will take up a significant part of the upcoming Board meeting. As such, this alone merits a later release of the third quarter report.

Eevia has therefore decided to postpone the Interim Report for Q3-24 to November 29, 2024.

 

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: stein.ulve@eeviahealth.com  or  investor@eeviahealth.com                     

Telephone: +358 400 22 5967                         

 

 

 

 

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as Bilberry, lingonberry, Chaga mushroom, and pine bark, are wild-harvested sustainably.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name (ticker) EEVIA.

To learn more, please visit  www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.